Asset
Isuventatug
Cullinan Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06381141 | phase1 | active_not_recruiting | 2024-09-03 | 2026-09-01 | Cullinan Therapeutics Inc. | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma |
| NCT05117476 | phase1 | active_not_recruiting | 2021-10-29 | 2026-03-01 | Cullinan Therapeutics Inc. | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.